Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.08 | -6.25% | -0.01 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
BB Squeeze Started | Range Contraction | 0.00% | |
Gapped Down | Weakness | 0.00% | |
20 DMA Support | Bullish | -6.25% | |
Upper Bollinger Band Walk | Strength | -6.25% | |
BB Squeeze Ended | Range Expansion | -6.25% | |
Upper Bollinger Band Touch | Strength | -6.25% |
Alert | Time |
---|---|
Possible NR7 | about 10 hours ago |
60 Minute Opening Range Breakdown | about 11 hours ago |
20 DMA Resistance | about 11 hours ago |
Fell Below 20 DMA | about 11 hours ago |
10 DMA Support | about 12 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/28/2024
Aridis Pharmaceuticals Inc. Description
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Immunotherapy Infectious Diseases Antibodies Monoclonal Antibodies Monoclonal Antibody Infection Bacterial Infections Bacterial Disease Staphylococcus Aureus Human Monoclonal Antibodies Pathogenic Bacteria Drug Resistance Pneumonia Pseudomonas Aeruginosa Targeted Immunotherapy Immunoglobulin M
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.5395 |
52 Week Low | 0.05 |
Average Volume | 111,519 |
200-Day Moving Average | 0.13 |
50-Day Moving Average | 0.07 |
20-Day Moving Average | 0.08 |
10-Day Moving Average | 0.08 |
Average True Range | 0.01 |
RSI (14) | 50.25 |
ADX | 49.56 |
+DI | 15.95 |
-DI | 5.18 |
Chandelier Exit (Long, 3 ATRs) | 0.06 |
Chandelier Exit (Short, 3 ATRs) | 0.09 |
Upper Bollinger Bands | 0.08 |
Lower Bollinger Band | 0.07 |
Percent B (%b) | 0.39 |
BandWidth | 15.47 |
MACD Line | 0.00 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.08 | ||||
Resistance 3 (R3) | 0.08 | 0.08 | 0.08 | ||
Resistance 2 (R2) | 0.08 | 0.08 | 0.08 | 0.08 | |
Resistance 1 (R1) | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Pivot Point | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Support 1 (S1) | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
Support 2 (S2) | 0.07 | 0.07 | 0.07 | 0.07 | |
Support 3 (S3) | 0.07 | 0.07 | 0.07 | ||
Support 4 (S4) | 0.07 |